Case Report: CD19 and CD22 CAR-T therapy induced durable complete remission in a patient with refractory plasmablastic lymphoma
IntroductionPlasmablastic lymphoma (PBL) is a rare and highly aggressive form of non-Hodgkin lymphoma that is associated with a poor prognosis. Traditional chemotherapy has demonstrated limited efficacy for PBL. There is currently no standard treatment for patients with refractory or relapsing PBL....
שמור ב:
| Principais autores: | , , , , , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Frontiers Media S.A.
2025-10-01
|
| סדרה: | Frontiers in Immunology |
| נושאים: | |
| גישה מקוונת: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1697566/full |
| תגים: |
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|